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Abstract. Imatinib mesylate (IM) is a compound that inhibits both BCR-ABL tyrosine kinase and c-kit receptors. Tyrosine
kinases are important in cellular signaling and mediate major cellular processes such as proliferation, differentiation, apoptosis,
attachment, and migration. Twenty-six albino rabbits were injected with 1×106 human uveal melanoma (UM) cells (92.1) into
the suprachoroidal space. Animals were immunosuppressed (cyclosporin A) over the course of the 12-week experiment and
divided into two groups (n = 13). The experimental group received IM once daily by gavage while the control group received
a placebo. One animal per group was sacrificed every week after the 2nd week. Upon necropsy, organs were harvested for
histopathological examination. Cells from the primary tumors were recultured and tested in proliferation and invasion assays.
A PCR array was used to investigate the differences in expression of 84 genes related to tumor metastasis. In the treated group,
4 rabbits developed intraocular tumors, with an average largest tumor dimension (LTD) of 2.5 mm and 5 animals reported
metastatic disease. Whereas 6 rabbits in the control group developed intraocular tumors, with an average LTD of 5.8 mm and 6
animals reported metastatic disease. The recultured cells from the treated group demonstrated lower proliferation rates and were
less invasive (p < 0.001). The PCR array showed differences in expression of genes related to metastasis. Notably, there was
290-fold increase in SERPINB5, a tumor suppressor gene, and a 10-fold higher expression of KISS1, a metastasis suppressor
gene, in the treated group. Proangiogenic genes such as VEGFA, PDGFA and PDGFB were downregulated in the treated group.
To the best of our knowledge, this is the first report detailing the altered expression of specific genes in UM cells after treatment
with IM.
1. Introduction
Metastatic uveal melanoma (UM) still presents
a challenge to ophthalmologists and oncologists.
1 Part of this work was presented as a poster at the 2009 ARVO
meeting.
∗Corresponding author: Bruno F. Fernandes, 3775 University
Street, Room 216, Montreal, Quebec H3A-2B4, Canada. Tel.: +1
514 398 7192 ext. 00384; Fax: +1 514 398 5728; E-mail: bruno.
mtl@gmail.com.
Despite successful control of the primary tumor, sur-
vival rates have remained markedly unchanged. Once
metastases are detected, prognosis is poor and almost
every patient dies within a year [1]. Several centers
have tried different compounds, but the need for a suit-
able and effective drug that would actually improve the
survival of metastatic melanoma patients is desirable.
Imatinib mesylate (IM) is a compound that inhibits
various tyrosine kinases includings c-kit [2] and BCR-
ABL [3]. Tyrosine kinases are important in cellular
signaling and mediate major cellular processes such
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as proliferation, differentiation, apoptosis, attachment,
and migration [4]. Previous work from our labora-
tory has demonstrated that 78% of UM express c-kit.
Moreover, treatment of UM cell lines with IM inhibits
proliferation and their invasive abilities [5]. In this
study, we therefore aimed to assess the in vivo effects
of IM in an animal model of UM.
2. Methods
The animal model was carried out in compliance
with the Association of Research in Vision and Oph-
thalmology Statement for the Use of Animals in
Ophthalmic and Vision Research. The approval of both
the Animal Care Committee and the Ethics Subcom-
mittee at McGill University was obtained prior to all
experiments.
2.1. Animals
Twenty-six male New Zealand albino rabbits
(Charles River Canada, St-Constant, Que´bec, Canada)
were randomly divided into two groups, control and
experimental, with mean initial weights of 2.73 ±
0.11 kg and 2.79 ± 0.13 kg respectively. The animals
were immunosuppressed using daily intramuscu-
lar injections of cyclosporin A (CsA; Sandimmune
50 mg/ml, Novartis Pharmaceuticals Canada Inc.,
Dorval, Que´bec, Canada) in order to avoid rejection of
the human cells. CsA administration was maintained
throughout the 12-week experiment to prevent tumor
regression. The dosage schedule recommended in pre-
vious studies [6–8] was employed: 15 mg/kg/day, 3
days before cell inoculation and during 4 weeks there-
after, followed by 10 mg/kg/day during the last 8 weeks
of the experiment [9]. CsA doses were adjusted weekly
according to the animal weight to compensate for
decreased animal weight and avoid possible toxicity.
2.2. Cell lines
The 92.1 primary human uveal melanoma cell line
[10], kindly provided by Dr. Antonia Saornil from the
Instituto Universitario de Oftalmobiolog´ia Aplicada
(IOBA), University of Valladolid, was used. One
million cells (cellular viability greater than 98%,
determined by the trypan blue exclusion test) were
suspended in 0.1 ml of RPMI-1640 media (Invitro-
gen, Burlington, Ontario, Canada) and injected into
the suprachoroidal space of the right eye of each rabbit
according to a previously described technique [6–9].
2.3. Drug administration
Dose calculation for rabbits was done using the
body surface area (BSA) normalization method. Based
on that, we administered a dose of 260 mg/m2 of
IM (Novartis Pharma AG, Basel, Switzerland) which
was usually 18–20 mg/kg depending on the animal’s
weight. Doses were adjusted accordingly as the ani-
mals lost weight over the course of the experiment to
avoid toxicity. The dose used is the dose recommend
for treatment in children and equivalent to 476 mg in a
70 kg adult.
2.4. Histopathological studies
One animal per group was euthanized per week start-
ing on the second week after the inoculation of cells.
The selection criterion was based on the appearance of
the animal, signs of CsA toxicity and veterinary rec-
ommendations. The remaining rabbits of each group
(N = 3) were sacrificed at the end of the experiment.
The method of euthanasia was exsanguination follow-
ing anesthesia using intramuscular ketamine-xylazine
(35 mg/kg-5 mg/kg). An autopsy was performed on
every animal that was sacrificed. The enucleated eyes
and other organs with possible metastatic disease such
as lungs, livers and kidneys were collected, macro-
scopically examined and preserved in 10% phosphate
buffered formalin. Formalin-fixed, paraffin-embedded
sections of the collected specimens were stained with
Hematoxylin and Eosin (H&E) for histopathological
assessment.
2.5. In vitro assays
The eye of each rabbit was processed prior to for-
malin fixation in order to acquire fresh tumor samples.
Cell harvesting and reculturing was successful in 3
animals from each group. Cells were cultured in a
6-well plate in 5% fetal bovine serum (FBS) supple-
mented RPMI and grown to confluence before seeding
for proliferation and invasion assay experiments. The
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Sulforhodamine-B based assay kit (TOX-6, Sigma-
Aldrich, St. Louis, Missouri, USA) was performed
according to the National Cancer Institute protocol
[11]. Recultured cells obtained from primary tumors
were seeded in a 96-well plate at a concentration of
2.5×103cells per well, with six wells per cell line.
Cells were allowed to adhere overnight and incubate
for 48 or 72 hours. Following both the 48 and 72 hour
incubation periods, cells were fixed to the bottom of
the wells using a solution of 50% Trichloroacetic acid
(TCA) (Fisher Scientific Company, Ottawa, Ontario,
Canada) for 1 hour at 4◦C. Plates were then rinsed with
distilled water to remove the TCA and excess media
and were air-dried. The Sulforhodamine-B dye solu-
tion was then added to each well and allowed to stain
for 30 minutes. The Sulforhodamine-B solution was
subsequently removed by washing with a 1% acetic
acid solution and once more allowed to air dry. The
dye that had become incorporated into the fixed cells
at the bottom of the wells was solubilized in a 10 mM
solution of Tris base solution. The absorbance of the
solute was measured using a microplate reader at a
wavelength of 565 nm.
For the invasion assay, a modified Boyden cham-
ber consisting of polyethylene terephthalate membrane
with 8m diameter pores precoated with Matrigel,
an artificial basement membrane (BD, Mississauga,
Ontario, Canada), was used [12]. A polyethylene
terephthalate membrane without Matrigel was used as
a control. Briefly, 1.25×105 cells from both groups
were added to the upper chamber in RPMI 1640 with
0.1% FBS. RPMI 1640 with 10% fetal bovine serum
was added to the lower chamber as a chemoattrac-
tant. The chambers were then incubated at 37◦C in
5% CO2-enriched atmosphere for 48 h to allow for
cellular invasion through the Matrigel. Non-invading
cells were removed from the upper chamber by gently
wiping the surface of the membrane with a moist cot-
ton swab. Membranes were removed and then stained
using a Diff-Quick staining set. Stained cells were
counted microscopically in 20 high-powered (400×)
fields. Only cells whose nuclei had completely invaded
through the membrane were counted. Each experimen-
tal condition was done in triplicate and the average
number of invading cells was then calculated. Per-
centage invasion was determined using the following
formula: % invasion = (mean number of cells invading
through the Matrigel/mean number of cells migrating
through control polyethylene terephthalate membrane)
multiplied by one hundred.
2.6. Statistical analysis
The differences in proliferation and invasion rates
for each uveal melanoma cell line from each rabbit
were determined using the ANOVA test. A p-value of
less than 0.05 was considered statistically significant.
Calculations were computer-based using SPSS version
11.5 (SPSS Inc., Chicago, Illinois, USA).
2.7. PCR array
The Human Tumor Metastasis RT² Profiler PCR
Array (Qiagen, Mississauga, Ontario, Canada) was
employed in this study. In order to conform to the
Bio-Rad Opticon Chromo4 thermocycler.Plate (MJ
Research, Waltham, Massachusetts, USA) array for-
mat D was used. The array includes 84 genes known
to contribute to or prevent metastatic disease. In addi-
tion, five housekeeping genes, a genomic DNA control,
and three positive controls are included to ensure high
quality data normalization across samples. Two pri-
mary tumors, one from each group, were chosen for
this experiment, (R6, R27). These two specific rab-
bits were chosen because they were the ones that had
the longest clinical endpoint throughout the entire 12-
week experiment. Total RNA was extracted from these
samples using the RNeasy Mini Kit (Qiagen) following
the protocol for isolation from animal cells. The RT2
First Strand Kit (Qiagen) was used in order to produce
a cDNA library of the total RNA extracted. The cDNA




In the treated group, 4 rabbits developed intraoc-
ular tumors, with an average largest tumor dimension
(LTD) of 2.5 mm and 5 animals reported metastatic dis-
ease. Whereas 6 rabbits in the control group developed
intraocular tumors, with an average LTD of 5.8 mm and
6 animals reported metastatic disease. Metastases were
seen only in the lungs (Fig. 1). Csa toxicity was gen-
erally low and not significant enough to bias the study.
Because of the deterioration of the animal’s condition
were primarily due to tumor burden, the sequential sac-




Fig. 1. Gross examination of post-mortem specimens: A) Enucleated eye from an animal of the control group harboring a large whitish intraocular
tumor occupying almost half of the vitreal cavity. B) An eye from the group treated with Imatinib mesylate showing a much smaller tumor
(arrows). C) White nodules representing metastatic dissemination to the lung. D) A cross-section of the lung showing a metastatic nodule
(arrows). Microscopic images: E) Intraocular tumor, epithelioid cell-type with several mitotic figures (H&E, ×200). F) Metastatic nodule
revealing the malignant cells interspersed with an inflammatory infiltrate (H&E, ×200).
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rifice of animals roughly reproduced the natural history
of this particular animal model.
3.2. In vitro assays
The recultured cells from the treated group showed
lower proliferation rates after 24 and 48 hours of incu-
bation (p < 0.001). Cells from treated animals were
markedly less invasive (p < 0.001) (Fig. 2).
3.3. qPCR array
All 84 genes present on the Human Tumor Metas-
tasis RT² Profiler PCR Array panel were successfully
amplified in the primary tumor from both treated and
untreated rabbits (R6, R27). When both samples were
analyzed in comparison, with the SA Biosciences
software provided, a list of genes were significantly
different between the treated and control rabbits (± 2
fold relative change) (Table 1).
4. Discussion
The average life expectancy of UM patients that
develop metastasis is as short as 3.6 months [13].
When patients are screened regularly and metastasis
is discovered before the onset of symptoms, survival is
longer but most likely due to lead-time bias [14–16].
Various studies have supported this theory by show-
Fig. 2. Left) Changes in the proliferation rates (TOX-6) of recul-
tured cells from the intraocular tumor of animals treated with
Imatinib mesylate (y-axis = Optical density). Differences measured
after 24 and 48 h were both significant (P < 0.001). Right) The
invasive abilities of these cells were also significantly impaired
(y-axis = percentage invasion). White column, control group. Black
column, treated group.
ing that the apparent survival advantage in patients
diagnosed before the onset of symptoms is seen only
in the first year after diagnosis of metastasis. By the
second year, cumulative metastatic rates are 90% or
higher in both groups [17]. Several groups attempted
different therapeutic approaches to selected groups
of patients. Systemic therapies of liver metastases
produced a response rate of less than 1% [18]. Metas-
tectomy of localized nodules [19, 20], hepatic artery
infusion [21–23], chemoembolization [22, 24, 25] and
multi-drug systemic chemotherapy [26–29] have also
been tried but no therapy to date could indubitably
change the natural history of the disease. Augsburger
et al. [1] have recently reviewed in depth the available
literature regarding the treatment of metastatic UM and
no randomized phase III clinical trials comparing any
treatment against observation have been reported. The
apparent prolonged survival presented by some centers
Table 1
Changes in gene expression after treatment with Imatinib mesylate
in an animal model of uveal melanoma
Downregulated Upregulated
Gene Fold change Gene Fold change
COL18A1 −44.51 SERPINB5 290.82
SNCG −30.33 CCNE1 10.88
NME4 −11.52 KISS1 10.04
IGF1 −11.05 MMP10 5.49
PDGFA −8.36 HPSE 5.49
FOS −6.90 CDC25A 5.28
EPDR1 −6.80 RORB 5.27
MCAM −5.54 ITGA2 5.07
JUN −4.62 MMP7 4.92
VEGFA −4.03 MMP13 4.59
TIMP3 −3.73 BRCA1 4.30
FGFR2 −3.71 SSTR2 4.22
MYC −3.65 GZMA 3.79
S100A4 −3.64 TNF 3.23
BCL2L1 −3.53 HGF 3.22
MTSS1 −3.42 PNN 3.19
MYC −3.34 MYCL1 2.84
BAD −3.18 CCL7 2.79
CDKN2A −3.17 CDH1 2.79
ITGB5 −3.16 CTSL1 2.79
IFNA1 −3.12 CXCR4 2.79
TNFRSF1A −3.00 KISS1 R 2.79
IFNB1 −2.91 MTSS1 2.79
IL18 −2.81 SYK 2.79
CDKN1A −2.69 TIMP4 2.79
TP53 −2.54 CDK2 2.78
AKT1 −2.38 IL8RB 2.51
ITGA3 −2.37 PLAUR 2.49
PDGFB −2.28 MMP3 2.36
CD82 −2.16 CASP8 2.35
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is likely the result of selection, surveillance or publica-
tion biases. As a result, there is a need to develop new
effective therapies for metastatic UM.
IM is a tyrosine kinase inhibitor of the Abelson
kinase (ABL) that also inhibits the receptor tyrosine
kinases (RTKs) KIT and platelet-derived growth factor
receptor [30]. IM has been approved by the Food and
Drug Administration (FDA) to treat c-kit positive GIST
and Philadelphia-chromosome-positive chronic myel-
ogenous leukemia [31]. Response rates are as high as
90% for those two malignancies [30]. Treatment with
IM is generally well tolerated with a low incidence of
severe side effects. The most common adverse events
include mild to moderate edema, muscle cramps, diar-
rhea, nausea, skin rashes, and myelosuppression [32].
C-kit is also considered a potential target in a wide vari-
ety of other human malignancies where it is expressed
and associated with prognosis [5].
To date, the potential use of IM for metastatic UM
has been linked to c-kit as the molecular target. That
resulted from studies showing high expression of c-kit
in primary and metastatic UM [5, 33], even though c-kit
mutations have not been found [33, 34]. In vitro stud-
ies provided more information implicating c-kit in the
tumorigenesis of UM [2] and that the c-kit molecular
pathway may be important in UM growth [4]. How-
ever, data on human patients is rather limited. The first
attempt to treat five cases of metastatic UM showed
modest results in c-kit positive patients [35], while
negative patients showed disease progression. A more
recent trial on 12 patients with advanced UM did not
observe any objective response [33].
Nonetheless, our findings not only support the idea
that IM is still a promising drug for the treatment of
metastatic melanoma, but also provide some insight
into why previous trials did not succeed. In our animal
model, the treatment with IM caused a 10-fold upreg-
ulation of KISS1, which was identified as a human
melanoma metastasis suppressor gene [36]. We treated
additional UM cell lines in vitro and confirmed the
upregulation of KISS1 by IM (data not shown). Sup-
porting the role of KISS1 as a MSG, other investigators
showed that transfection of KISS1 into metastatic
human melanoma cell lines suppressed metastasis in
athymic nude mice by 95% [37]. The role of KISS1 in
preventing metastases seems to be related to keeping
cells in their dormant state [38]. Therefore, using IM
after the detection of macrometastasis is unlikely to
cause any impact on the final outcome. By then, cells
have already “awaken” from their dormant state, and
KISS1 would not play a significant role anymore. Inter-
estingly, KISS1 is indeed related to prognosis in UM:
Decreased expression of KISS1 in primary UM is asso-
ciated with decreased survival and higher metastatic
rates [39]. The upregulation of a metastasis suppressor
gene by IM was an interesting finding that is currently
being studied at our laboratory. The drug might be
able to prolong the dormancy phase of the disease and
finally make a positive impact in the prognosis.
Moreover, IM also altered the expression of other
genes that are implicated in the formation of neoves-
sels, which are essential for the evolution of the
pre-metastatic niche. On the group of downregulated
genes we found Collagen XVIII, a precursor of endo-
statin, whose high expression has been correlated with
poor outcome in lung cancer [40]. PDGFA, PDGFB
and VEGFA, all known angiogenic factors that play
a critical role in cancer angiogenesis [41, 42], were
also downregulated. For the group of genes that were
upregulated, there was a striking 290-fold increased
expression of SERPINB5, also known as Maspin.
Maspin (mammary serine protease inhibitor) is a 42-
kDa protein and belongs to the serine protease inhibitor
superfamily [43]. The tumor-suppressive function of
Maspin is due to inhibition of motility, invasiveness,
angiogenesis, and increased sensitivity to apoptosis
[44]. The expression of Maspin is higher in low-
risk gastrointestinal stromal tumors when compared
to high-risk patients [45]. For cutaneous melanoma,
maspin expression was correlated with decreased
tumor vessel density and thickness and the expres-
sion is lost during the transition from radial to vertical
growth phase [46]. As a result, maspin is consid-
ered as a tumor suppressor in melanoma by impairing
tumor angiogenesis. Aside from impairing neovascu-
larization, IM also caused the downregulation of genes
associated with resistance to anticancer drugs and eva-
sion of apoptosis, namely, IGF1 and BCL2L1 [47, 48].
We do acknowledge that our findings do not answer
the question whether c-kit or other tyrosine kinases
are involved or not in the oncogenesis of UM. Addi-
tionally, we cannot assure that IM will be successful
for the treatment of patients with advanced metastatic
disease. Currently, UM is considered a systemic dis-
ease in which cells have already escaped the primary
site by the time the primary lesion is diagnosed. The
interesting finding of our study is that we revealed
another mechanism of action for IM, independent of c-
kit expression or mutation in UM cells. In keeping with
our findings, other investigators confirmed that IM tar-
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gets PDGF signaling in cancer cells and reduces tumor
growth. Not only tumor cells but also host smooth
muscle neighboring cells (SMC) are affected by IM
translating into a decrease in tumor microvessel den-
sity and number of SMC-presenting vessels [49]. The
result is that not only the “seed” but also the “soil”
are changed in a way that impairs the development
of the metastatic foci. Therefore, despite disappoint-
ing initial results for the treatment of human patients
with metastatic melanoma [33, 35] we still consider
IM as a potential therapy and further research is war-
ranted. We would suggest that future trials be done with
patients that are at high-risk of developing metastatic
disease, but have not yet presented clinical evidence
of such. High-risk UM patients can be identified based
on chromossome mutations and genetic signatures in
addition to the conventional clinical, histopathological
and immunohistochemical prognostic factors. Offer-
ing IM treatment to terminal patients is unlikely to
change the course of the disease.
In summary, the treatment with IM correlated
with fewer and smaller primary tumors as well as
less metastatic disease. The previously demonstrated
in vitro effects of IM were confirmed in this animal
model, specifically lower proliferation and invasion
rates for the recultured cells. Interestingly, IM altered
the expression of genes known to be related to metas-
tasis but previously not attributed to the action of
IM. The upregulation of KISS1 and Maspin, and the
downregulation of several proangiogenic factors by
the systemic administration of IM may prove bene-
ficial during the preclinical stage of metastatic UM by
maintaining microscopic metastatic cells dormant and
thereby prolonging “disease-free” survival.
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